Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Elliott

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Harm Reduction Journal|July 28, 2017
Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworksElaine Hyshka, Jalene Anderson-Baron, Kamagaju Karekezi, et al.
The Journal of Biological Chemistry|June 9, 2016
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaDaniel Beck, Jenny Zobel, Ruth Barber, et al.
The International Journal on Drug Policy|April 29, 2017
Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015T Cameron Wild, Bernie Pauly, Lynne Belle-Isle, et al.
Plos One|May 19, 2021
Public support for harm reduction: A population survey of Canadian adultsT Cameron Wild, Jakob Koziel, Jalene Anderson-Baron, et al.
Pediatric Surgery International|August 31, 2017
Enhancing recovery after minimally invasive repair of pectus excavatumCristen N Litz, Sandra M Farach, Allison M Fernandez, et al.
Journal of Pediatric Surgery|April 6, 2017
Percutaneous ultrasound-guided vs. intraoperative rectus sheath block for pediatric umbilical hernia repair: A randomized clinical trialCristen N Litz, Sandra M Farach, Allison M Fernandez, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2009
Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs)Nick Bailey, Mark J Bamford, Delphine Brissy, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
Cancer Research|March 30, 2016
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast CancerMaria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, et al.
Scientific Reports|January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsMalini Menon, Richard Elliott, Leandra Bowers, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Harm Reduction Journal|July 28, 2017
Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworksElaine Hyshka, Jalene Anderson-Baron, Kamagaju Karekezi, et al.
The Journal of Biological Chemistry|June 9, 2016
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaDaniel Beck, Jenny Zobel, Ruth Barber, et al.
The International Journal on Drug Policy|April 29, 2017
Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015T Cameron Wild, Bernie Pauly, Lynne Belle-Isle, et al.
Plos One|May 19, 2021
Public support for harm reduction: A population survey of Canadian adultsT Cameron Wild, Jakob Koziel, Jalene Anderson-Baron, et al.
Pediatric Surgery International|August 31, 2017
Enhancing recovery after minimally invasive repair of pectus excavatumCristen N Litz, Sandra M Farach, Allison M Fernandez, et al.
Journal of Pediatric Surgery|April 6, 2017
Percutaneous ultrasound-guided vs. intraoperative rectus sheath block for pediatric umbilical hernia repair: A randomized clinical trialCristen N Litz, Sandra M Farach, Allison M Fernandez, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2009
Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs)Nick Bailey, Mark J Bamford, Delphine Brissy, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
Cancer Research|March 30, 2016
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast CancerMaria Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, et al.
Scientific Reports|January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitorsMalini Menon, Richard Elliott, Leandra Bowers, et al.
Pageof 11